Haemonetics Co. (NYSE:HAE) Shares Sold by Royce & Associates LP

Royce & Associates LP lowered its position in Haemonetics Co. (NYSE:HAE - Free Report) by 4.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,153,268 shares of the medical instruments supplier's stock after selling 57,278 shares during the period. Haemonetics makes up approximately 0.8% of Royce & Associates LP's investment portfolio, making the stock its 7th biggest holding. Royce & Associates LP owned approximately 2.30% of Haemonetics worth $90,047,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Wellington Management Group LLP increased its stake in Haemonetics by 9.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier's stock worth $337,722,000 after buying an additional 363,702 shares during the period. Geode Capital Management LLC increased its position in shares of Haemonetics by 1.8% during the third quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier's stock worth $95,986,000 after acquiring an additional 21,547 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of Haemonetics by 29.5% during the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier's stock valued at $88,433,000 after acquiring an additional 250,833 shares in the last quarter. Boston Trust Walden Corp boosted its holdings in shares of Haemonetics by 13.1% in the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock valued at $71,500,000 after purchasing an additional 106,114 shares during the period. Finally, Westfield Capital Management Co. LP grew its stake in Haemonetics by 10.9% in the third quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier's stock worth $66,206,000 after purchasing an additional 80,783 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Remove Ads

Haemonetics Stock Down 1.5 %

Shares of HAE traded down $0.95 during midday trading on Thursday, hitting $64.28. 614,717 shares of the company's stock traded hands, compared to its average volume of 648,796. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $3.23 billion, a price-to-earnings ratio of 25.31, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97. The firm's fifty day moving average is $67.82 and its 200-day moving average is $75.19.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, sell-side analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. JMP Securities lowered their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a report on Friday, February 7th. Raymond James reaffirmed a "strong-buy" rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Needham & Company LLC cut their target price on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research report on Tuesday. Barrington Research lowered their price target on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Finally, Bank of America downgraded shares of Haemonetics from a "neutral" rating to an "underperform" rating and reduced their price objective for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.